You are viewing: Europe Pharmaceutical Contract Manufacturing Market analysis

The Europe Pharmaceutical Contract Manufacturing Market was valued at $58650 Million in 2025 and projected to reach to $85530 Million by 2030, representing a compound annual growth rate of 7.8%. Europe's pharmaceutical contract manufacturing market is poised for sustained growth through 2030, driven by increasing pharmaceutical R&D outsourcing, rising demand for biologics manufacturing, and the region's established regulatory credibility.

Europe Pharmaceutical Contract Manufacturing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Pharmaceutical Contract Manufacturing Market Trends and Insights

  • Europe maintains a strong position in global contract manufacturing, driven by stringent regulatory frameworks, advanced infrastructure, and a concentration of biopharmaceutical innovation hubs.
  • The region's established quality standards and skilled workforce continue to attract pharmaceutical companies seeking reliable outsourcing partners. The European market benefits from increasing demand for specialized manufacturing services, including biologics, sterile injectables, and complex formulations.
  • Europe's commitment to sustainability and digital transformation in manufacturing processes further enhances its competitive advantage.
  • Between 2025 and 2030, Europe is expected to capture significant market share as companies prioritize nearshoring and supply chain resilience within the region. Key drivers for Europe's growth include rising R&D investments, regulatory harmonization through the European Medicines Agency, and the expansion of contract manufacturing capacity to support both domestic and international pharmaceutical companies.
  • Europe's strategic position as a bridge between global markets positions it as a critical hub for contract manufacturing services through 2030..

Key Market Statistics

  • CAGR (2025-2030) 7.8% CAGR
  • Market Size, 2025 ~USD 58650 Million
  • Forecast, 2030 ~USD 85530 Million
  • Geography Europe

Europe Pharmaceutical Contract Manufacturing Market Overview

Market Valuation & Growth :

Europe's pharmaceutical contract manufacturing market is valued at $58.65 billion in 2025 and is projected to reach $85.53 billion by 2030, with a CAGR of 7.8%, demonstrating robust expansion driven by increasing outsourcing demand.

Regulatory Excellence & Compliance :

Europe benefits from stringent regulatory frameworks including EMA guidelines and GMP standards, positioning the region as a trusted hub for high-quality contract manufacturing services that meet global compliance requirements.

Biopharmaceutical Innovation Hubs :

The region hosts concentrated clusters of biopharmaceutical innovation, particularly in Germany, UK, and Switzerland, attracting significant investment in advanced manufacturing technologies and specialized contract manufacturing capabilities.

Advanced Infrastructure & Capacity :

Europe maintains state-of-the-art manufacturing facilities with cutting-edge infrastructure, supporting both small molecule and biologics production, enabling contract manufacturers to serve diverse pharmaceutical development needs.

Europe Pharmaceutical Contract Manufacturing Market Dynamics

  • The market benefits from strategic investments in advanced manufacturing technologies, including continuous manufacturing and automation, which enhance operational efficiency and reduce time-to-market for pharmaceutical products. Key growth catalysts include the expansion of biopharmaceutical pipelines, growing demand for specialized manufacturing services, and increased partnerships between pharmaceutical companies and contract manufacturers.
  • Europe's competitive advantage in regulatory compliance, skilled workforce, and innovation infrastructure positions it as a preferred destination for global pharmaceutical outsourcing, supporting the projected 7.8% CAGR through 2030..

Related Ecosystem

Medical Devices

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Magnetic Resonance Imaging (MRI)
  • Disposable Autoinjectors
  • Pulse Oximeters
  • Blood Pressure Monitors
Top Companies
  • Medtronic plc
  • Abbott Laboratories
  • Stryker Corporation
  • Becton, Dickinson and Company
  • JOHNSON & JOHNSON

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • SANOFI
    • Merck KGaA
    • NOVARTIS
    • Pfizer Inc.

      Key Takeaways

      • Europe's pharmaceutical contract manufacturing market will grow from $58.65B (2025) to $85.53B (2030) at a 7.8% CAGR, reflecting strong regional demand.
      • Europe's regulatory excellence and advanced infrastructure position the region as a preferred outsourcing destination for global pharmaceutical companies.
      • Nearshoring trends and supply chain resilience initiatives are driving increased contract manufacturing investments across Europe through 2030.
      • Specialized services including biologics and sterile injectables are key growth segments within Europe's contract manufacturing landscape.

      Pharmaceutical Contract Manufacturing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment DRUG DEVELOPMENT SERVICES (Service)
      Forecast Period 2025-2030
      Growth Rate CAGR of 8.2% from 2025 to 2030
      Largest Segment PHARMACEUTICAL MANUFACTURING SERVICES (Service)
      Market Size Base Year (Billions) ~USD 210.35 (2025)
      Revenue Forecast (Billions) ~USD 311.95 (2030)
      Segments Covered Service, Type, Molecule, End User

      Europe Pharmaceutical Contract Manufacturing Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Service

      • Biologics Manufacturing Services
      • Drug Development Services
      • Fill-Finish Services
      • Other Services
      • Packaging & Labeling Services
      • Packaging & Labelling Services
      • Pharmaceutical Manufacturing Services

      By Type

      • Adc
      • Antibody Drug Conjugates
      • Biologics Api Manufacturing Services
      • Biologics Fdf Manufacturing Services
      • Capsule Manufacturing Services
      • Cell & Gene Therapies
      • Cgt
      • High-Potency Small Molecule
      • High-Potency Small Molecules
      • Mabs
      • Monoclonal Antibodies
      • Oligonucleotide & Synthetic Peptides
      • Oligonucleotides & Synthetic Peptides
      • Oral Liquid Manufacturing Services
      • Other Fdf Manufacturing Services
      • Other Large Molecules
      • Other Small Molecules
      • Parenteral Manufacturing Services
      • Pharmaceutical Api Manufacturing Services
      • Pharmaceutical Fdf Manufacturing Services
      • Radiopharmaceutical Molecules
      • Semi-Solid Manufacturing Services
      • Tablet Manufacturing Services
      • Therapeutic Peptides & Proteins
      • Vaccines

      By Molecule

      • Large Molecules
      • Small Molecules

      By End User

      • Big Pharmaceutical Companies
      • Generic Pharmaceutical Companies
      • Other End Users
      • Small & Medium-Sized Pharmaceutical Companies

      Target Audience

      • Pharmaceutical Companies : Identify optimal contract manufacturing partners across Europe, evaluate regional capacity, and develop outsourcing strategies aligned with regulatory requirements and cost-efficiency objectives.
      • Contract Manufacturers (CDMOs/CMOs) : Benchmark competitive positioning, identify market expansion opportunities, assess regional demand trends, and develop growth strategies within Europe's high-value pharmaceutical manufacturing sector.
      • Investment & Private Equity Firms : Evaluate investment opportunities in European contract manufacturing assets, assess market consolidation trends, and identify acquisition targets with strong growth potential and regulatory credentials.
      • Healthcare Consultants & Advisors : Support client strategy development with comprehensive European market intelligence, competitive analysis, and regulatory insights for pharmaceutical outsourcing and manufacturing decisions.
      • Regulatory & Compliance Officers : Stay informed on Europe-specific regulatory frameworks, GMP standards, and compliance requirements essential for managing pharmaceutical manufacturing operations and partnerships across the region.

      Europe vs. other regions

      HowEurope compares to the other 3 regional blocs covered in this market.

      North America
      ~USD 127140 Million · 8.4% wtd CAGR ·
      Asia Pacific
      ~USD 64270 Million · 9.4% wtd CAGR ·
      Latin America
      ~USD 13690 Million · 7% wtd CAGR ·

      Countries within Europe - compare and drill down

      Country2025 size (native)
      GermanyUSD 20390 Million
      UKUSD 17150 Million
      FranceUSD 6680 Million
      ItalyUSD 3630 Million
      SwitzerlandUSD 2720 Million
      SpainUSD 2210 Million
      PolandUSD 1050 Million
      Rest Of EuropeUSD 9340 Million

      Country market size visualization

      Germany
      USD 20390 Million
      UK
      USD 17150 Million
      France
      USD 6680 Million
      Italy
      USD 3630 Million
      Switzerland
      USD 2720 Million
      Spain
      USD 2210 Million
      Poland
      USD 1050 Million
      Rest Of Europe
      USD 9340 Million

      Reasons to Buy this Report

      • Regional Market Segmentation : Gain detailed insights into Europe's pharmaceutical contract manufacturing landscape with country-level breakdowns including Germany ($20.39B), UK ($17.15B), France ($6.68B), and other key markets to identify regional opportunities.
      • Competitive Landscape Analysis : Understand the competitive positioning of European contract manufacturers, regulatory advantages, and market consolidation trends to benchmark against global players and identify partnership opportunities.
      • Growth Drivers & Market Dynamics : Access comprehensive analysis of Europe-specific growth drivers including regulatory frameworks, biopharmaceutical innovation clusters, and capacity expansion trends shaping the 7.8% CAGR through 2030.
      • Strategic Investment Guidance : Make informed investment and expansion decisions with detailed forecasts, capacity utilization trends, and emerging opportunities in specialized manufacturing segments across European markets.
      • Regulatory & Compliance Insights : Leverage Europe-specific regulatory intelligence, GMP compliance standards, and EMA requirements to navigate the region's stringent pharmaceutical manufacturing landscape effectively.

      Frequently asked questions

      What is the current size of Europe's pharmaceutical contract manufacturing market?

      Europe's pharmaceutical contract manufacturing market is valued at $58.65 billion in 2025 and is expected to reach $85.53 billion by 2030.

      What is the projected growth rate for Europe's contract manufacturing market?

      Europe's pharmaceutical contract manufacturing market is projected to grow at a compound annual growth rate (CAGR) of 7.8% from 2025 to 2030.

      Why is Europe a preferred location for pharmaceutical contract manufacturing?

      Europe is preferred due to stringent regulatory frameworks, advanced manufacturing infrastructure, skilled workforce, quality standards, and proximity to major pharmaceutical markets.

      What are the key growth drivers for Europe's contract manufacturing market?

      Key drivers include rising R&D investments, regulatory harmonization, nearshoring strategies, supply chain resilience initiatives, and demand for specialized services like biologics and sterile injectables.

      Which pharmaceutical services are experiencing the highest growth in Europe?

      Specialized manufacturing services including biologics, sterile injectables, and complex formulations are experiencing the highest growth in Europe's contract manufacturing market.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global pharmaceutical contract manufacturing market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

      Secondary Research

      Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the pharmaceutical contract manufacturing market. The secondary sources used for this study include Indian Pharmaceutical Association (IPA), Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Central Drugs Standard Control Organization (CDSCO), Indian Brand Equity Foundation (IBEF), European Medicines Agency (EMA), Pharma & Biopharma Outsourcing Association (PBOA), Generics and Biosimilars Initiative (GaBI), Pharma Times, Parenteral Drug Association (PDA), Indian Drug Manufacturers’ Association (IDMA), American Association of Pharmaceutical Scientists (AAPS), Global Cancer Observatory, American Chemical Society, National Center for Biotechnology Information, Eurostat, Food and Drug Administration (FDA), Biotechnology and Biological Sciences Research Council (BBSRC), Pharmaceutical Research and Manufacturers of America (PhRMA), World Journal of Pharmaceutical Sciences, research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

      Primary Research

      Following an initial assessment of the global pharmaceutical contract manufacturing market landscape through secondary research, comprehensive primary research was undertaken. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.

      The following is a breakdown of the primary respondents:

      Pharmaceutical Contract Manufacturing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both bottom-up and top-down approaches were used to estimate and validate the total size of the pharmaceutical contract manufacturing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • A list of the major global players operating in the pharmaceutical contract manufacturing market was generated.
      • The revenues generated from their pharmaceutical contract manufacturing product have been determined through annual reports and secondary sources (including paid databases)
      • The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
      • All assumptions, approaches, and individual shares/revenue estimates were validated through interviews with experts.

      Global Pharmaceutical Contract Manufacturing Market: Bottom-up and Top-down Approach

      Pharmaceutical Contract Manufacturing Market

      Data Triangulation

      After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Pharmaceutical contract manufacturing organizations (CMOs) provide contract-based, comprehensive services, such as drug development and manufacturing. CMOs offer manufacturing services for active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs). Different aspects of contract manufacturing, such as drug development & manufacturing, formulation development, and commercial pharmaceutical & biopharmaceutical manufacturing, have been considered in this report.

      Stakeholders

      • Contract Development & Manufacturing Organizations
      • Biotechnology and Pharmaceutical Companies
      • Academic and Research Institutions
      • Corporate Entities
      • Venture Capitalists
      • Regulatory Agencies
      • Industry Associations and Government Agencies
      • Pharmaceutical Distributors and Suppliers
      • Contract Research Organizations

      Report Objectives

      • To define, describe, and forecast the global pharmaceutical contract manufacturing market based on the service, molecule, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall pharmaceutical contract manufacturing market
      • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To profile the key players in the pharmaceutical contract manufacturing market and comprehensively analyze their service portfolios, market positions, and core competencies
      • To track and analyze competitive developments in the pharmaceutical contract manufacturing market, such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations
      • To benchmark players within the pharmaceutical contract manufacturing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

       

      Get the Full Pharmaceutical Contract Manufacturing Market Report

      Full forecast, segment splits, and company analysis for all Pharmaceutical Contract Manufacturing Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status